US Health Institute’s Genetic Research Launches New Patient Portal
|
By LabMedica International staff writers Posted on 10 Nov 2014 |
A new portal created for patients to enter health history has been designed to provide a new opportunity for investigators to obtain a better determination of the human genome.
The Clinical Genome Resource (ClinGen), a US National Institutes of Health (NIH; Bethesda, MD, USA)-funded resource focused on analyzing data from thousands of clinical genetics tests yearly, announced the launch of a new patient portal, GenomeConnect.
GenomeConnect was developed by a team of Geisinger Health System (Danville, PA, USA) investigators and collaborators from the ClinGen project to establish an online patient community, where people who previously had genetic testing can input their test results for analysis by the ClinGen team. The online portal strengthens the ClinGen laboratory database (ClinVar) by combining patient-entered health information with clinical laboratory data for a comprehensive database that helps clinicians and researchers better understand genetic variants and their impact on health. GenomeConnect also allows patients who underwent genetic testing to interact with each other in a secure online community.
“A data repository, even one as robust as ClinGen, is just the first piece of the pie when it comes to fully understanding the role genetics play in the prevention of disease and the development of treatments and therapies,” said Andrew Faucett, director of policy and education, Geisinger Health System. “By allowing patients to input additional medical information, GenomeConnect is designed to empower patients and allow them to contribute to our understanding of the human genome. Together with patients, we can learn more about the human genome and the ability to re-establish contact with patients and request additional information about their health information is critical to the clinical use of genetic testing.”
The Geisinger Genomic Council encourages the use of reference laboratories that have pledged to contribute past, present, and future genomic data to US databases in an effort to increase medical knowledge and optimize patient care. “In order to advance patient care and continue genomic work to help improve the interpretation of genetic variants, it is vital that data from clinical testing be made publicly available while simultaneously respecting patient confidentiality,” said Christa Lese Martin, a lead investigator of the ClinGen project and director of the Autism & Developmental Medicine Institute at Geisinger. “GenomeConnect honors both of these pledges and will pay long-term dividends in patient care by developing an unrivaled database of genetic and clinical information.”
Patient portals such as GenomeConnect make genomic discoveries possible by integrating data from a large number of patients. The project is enrolling an unlimited number of participants with genetic test results and their family members, and participation takes place completely online using a computer, smartphone, or tablet.
Geisinger Health System is an integrated health services organization recognized for its innovative use of the electronic health record (EHR), and the development of new care models such as ProvenHealth Navigator and ProvenCare.
Related Links:
Clinical Genome Resource
US National Institutes of Health
GenomeConnect patient portal
The Clinical Genome Resource (ClinGen), a US National Institutes of Health (NIH; Bethesda, MD, USA)-funded resource focused on analyzing data from thousands of clinical genetics tests yearly, announced the launch of a new patient portal, GenomeConnect.
GenomeConnect was developed by a team of Geisinger Health System (Danville, PA, USA) investigators and collaborators from the ClinGen project to establish an online patient community, where people who previously had genetic testing can input their test results for analysis by the ClinGen team. The online portal strengthens the ClinGen laboratory database (ClinVar) by combining patient-entered health information with clinical laboratory data for a comprehensive database that helps clinicians and researchers better understand genetic variants and their impact on health. GenomeConnect also allows patients who underwent genetic testing to interact with each other in a secure online community.
“A data repository, even one as robust as ClinGen, is just the first piece of the pie when it comes to fully understanding the role genetics play in the prevention of disease and the development of treatments and therapies,” said Andrew Faucett, director of policy and education, Geisinger Health System. “By allowing patients to input additional medical information, GenomeConnect is designed to empower patients and allow them to contribute to our understanding of the human genome. Together with patients, we can learn more about the human genome and the ability to re-establish contact with patients and request additional information about their health information is critical to the clinical use of genetic testing.”
The Geisinger Genomic Council encourages the use of reference laboratories that have pledged to contribute past, present, and future genomic data to US databases in an effort to increase medical knowledge and optimize patient care. “In order to advance patient care and continue genomic work to help improve the interpretation of genetic variants, it is vital that data from clinical testing be made publicly available while simultaneously respecting patient confidentiality,” said Christa Lese Martin, a lead investigator of the ClinGen project and director of the Autism & Developmental Medicine Institute at Geisinger. “GenomeConnect honors both of these pledges and will pay long-term dividends in patient care by developing an unrivaled database of genetic and clinical information.”
Patient portals such as GenomeConnect make genomic discoveries possible by integrating data from a large number of patients. The project is enrolling an unlimited number of participants with genetic test results and their family members, and participation takes place completely online using a computer, smartphone, or tablet.
Geisinger Health System is an integrated health services organization recognized for its innovative use of the electronic health record (EHR), and the development of new care models such as ProvenHealth Navigator and ProvenCare.
Related Links:
Clinical Genome Resource
US National Institutes of Health
GenomeConnect patient portal
Latest BioResearch News
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
Liver cancer remains a leading cause of cancer mortality worldwide, with incidence rising alongside the growing burden of metabolic liver disease. Early detection can substantially improve outcomes, yet... Read more
Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Liquid biopsy promises earlier cancer detection and agile treatment monitoring, but robust biomarkers that are stable and disease‑specific remain a hurdle. Circular RNAs (circRNAs) are structurally resilient... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelPartnership Brings Automated Pathology Archiving Solutions to U.S. Labs
Accurate retention and retrieval of pathology blocks and slides underpin timely, reliable cancer diagnoses, yet manual archiving remains labor-intensive and error-prone for many laboratories.... Read more







